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Abstract
Traditional breast cancer treatments such as surgery and radiotherapy contain many inherent limitations with regards to
incomplete and nonselective tumor ablation. Cold atomospheric plasma (CAP) is an ionized gas where the ion temperature
is close to room temperature. It contains electrons, charged particles, radicals, various excited molecules, UV photons and
transient electric fields. These various compositional elements have the potential to either enhance and promote cellular
activity, or disrupt and destroy them. In particular, based on this unique composition, CAP could offer a minimally-invasive
surgical approach allowing for specific cancer cell or tumor tissue removal without influencing healthy cells. Thus, the
objective of this research is to investigate a novel CAP-based therapy for selectively bone metastatic breast cancer
treatment. For this purpose, human metastatic breast cancer (BrCa) cells and bone marrow derived human mesenchymal
stem cells (MSCs) were separately treated with CAP, and behavioral changes were evaluated after 1, 3, and 5 days of culture.
With different treatment times, different BrCa and MSC cell responses were observed. Our results showed that BrCa cells
were more sensitive to these CAP treatments than MSCs under plasma dose conditions tested. It demonstrated that CAP
can selectively ablate metastatic BrCa cells in vitro without damaging healthy MSCs at the metastatic bone site. In addition,
our study showed that CAP treatment can significantly inhibit the migration and invasion of BrCa cells. The results suggest
the great potential of CAP for breast cancer therapy.
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Introduction
Breast cancer is the second leading cause of cancer deaths in
women. It is estimated that 232,340 new cases of invasive breast
cancer will be diagnosed in the United States and 39,620 women
will die of the disease in 2013, according to the American Cancer
Society. Breast cancer exhibits an affinity to metastasize to bone,
resulting in debilitating skeletal complications associated with
significant morbidity and poor prognosis. Roughly, 85% of
individuals eventually develop bone metastases in advanced breast
cancer [1]. The growth of disseminated tumor cells in the skeleton
requires tumor cells to inhabit the bone marrow wherein
metastatic breast cancer cells colonize the skeleton and interrupt
normal bone remodeling processes. Current breast cancer
treatment options such as surgery and radiotherapy contain severe
limitations with regards to nonselective and incomplete tumor
ablation. Thus, new treatments which can completely and
selectively ablate solid tumors and transient breast cancer cells
and tissues while keeping surrounding healthy cells and tissues
intact is highly desirable.
Plasma is an ionized medium that contains numerous active
components including electrons and ions, free radicals, reactive
molecules, and photons [2–4]. It can be categorized as either
thermal or non-thermal plasma [4]. Thermal plasma has been
widely used to modify material surfaces, which is generally
conducted in a vacuum [5,6]. Cold atmospheric plasma (CAP), a
non-thermal plasma, shows high electron temperatures but very
low gas temperatures due to a weak ionization rate [5]. Because of
the varied mass of CAP particles and constituents, thermodynamic
equilibrium of electron self-collision occurs much faster than
equilibrium between electrons and larger particles, such as ions
[6,7]. Thus, the overall plasma temperature is much lower than
the electron temperature, which is close to room temperature. As
an emerging technique for biomedical applications, CAP exposure
has been shown to be highly effective in germicidal and
sterilization, wound healing, blood coagulation, material surface
modifications and crosslinking and treatment of various diseases,
including cancer [8–14]. In particular, CAP can potentially offer a
minimally-invasive surgical approach allowing for specific cancer
cell or tumor tissue removal without influencing surrounding
healthy cells and tissues, thus making it a promising technology for
cancer therapy. Two possible underlying mechanisms for CAP’s
high selectivity towards cancer cells can be attributed to: (1)
complex CAP composition and (2) the different nature of cancer
cells and normal cells. Firstly, the variable cellular effects of CAP
may be explained by the complex chemical composition of the
CAP plume governed by the way the CAP is generated. Its
presence can promote specific chemical reactions between charged
particles and living cells triggering intracellular biochemical
reactions that would elicit desired breast cancer therapeutic effects
[15]. For example, reactive oxygen species (ROS, such as O, OH)
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are believed to be a major reason for cancer cell lysis [16] and
bacterial inactivation [17], although the contribution of each type
of the reactive species is still not well understood. In addition, the
selective effects of CAP may be attributed to the significant
difference of cancer cells and normal cells, thus rendering cancer
cells more susceptible to CAP [18]. The objective of this research
is to investigate a CAP-based therapy for the first time to
selectively ablate metastatic breast cancer cell in metastatic bone
site.
Traditionally, CAP has been developed to kill cells by utilizing
deposition of different ROS active particles and excited radical,
including UV photons [19]. Low dose of cold plasma treatment
may have little to no effect on cancer cells, while high doses may
ablate both cancer cells/tumor tissue and healthy cells/tissues. In
this study, we will optimize CAP treatment parameters to
selectively kill human metastatic breast cancer (BrCa) cells without
minimally influencing healthy human bone marrow mesenchymal
stem cells (MSCs).
For this purpose, three key CAP factors (i.e. treatment
condition, exposure time, and treatment frequency) were tuned
and evaluated. Firstly, we evaluated a series of CAP treatment
conditions’ (such as generator’s output voltage and resistance)
influence on MSC viability in vitro. After selecting the best
treatment condition (i.e., minimum negative influence on MSCs),
human metastatic MDA-MB-231 BrCa cells and MSCs with the
same cell density were separately treated for 0, 30, 60, 90, and
120 s under this condition. Furthermore, BrCa cells and MSCs
were cultured for 1, 3 and 5 days with daily CAP treatments (0,
30, 60 and 90 s). Cell growth and migration under designed CAP
treatment were compared and evaluated.
Materials and Methods
BrCa cell and MSC culture
Human metastatic MDA-MB-231 BrCa cells (ATCC) were
cultured in a complete media comprised of Dulbecco’s Modified
Eagle Medium (DMEM, Gibco) supplemented with 10% fetal
bovine serum (Atlanta Biologicals) and 5% penicillin streptomycin
solution (Invitrogen) and cultured under standard cell culture
conditions (37uC, a humidified, 5% CO2/95% air environment).
Primary MSCs were derived from healthy consenting donor’s
iliac crest (Female; Age: 27). They were obtained at Tulane
University under an IRB-approved protocol with informed
consent, distributed from the Texas A&M Health Science Center,
Institute for Regenerative Medicine and thoroughly characterized.
We had the fully executed Material Transfer Agreement that was
needed to obtain the cells. This provides verification that we in fact
did not obtain the cells from the donors themselves. MSCs
(passage #3–6) were cultured in a complete media comprised of
Alpha Minimum Essential Medium (a-MEM, Gibco) supplement-
ed with 16.5% fetal bovine serum, 1% (v/v) L-Glutamine
(Invitrogen), and 1% penicillin streptomycin solution and cultured
under standard cell culture conditions as described above.
CAP characterization
The CAP device can produce diverse chemically active species.
In our study, the CAP device consists of four blocks (Figure 1).
Block 1 is a DC power supply 60 V/6A (SPS-606 Insteak). Block 2
is configured with a centrally powered electrode 1 mm in diameter
and a ground outer electrode wrapped around a 4.5 mm diameter
quartz tube which is the part of cold plasma production. Block 2
mainly controls the positional three degrees of freedom, allowing
for rotational, vertical, and horizontal translation of the jet. Block
3 is made up of a capacitor, (VISHAY SPRAGUE-TVA1346-E3-
100 mF, 100 V, axial) a transistor (STGW38IH130D, 33 A-
1300 V-very fast IGBT), and a LM555 timer. LM555 timer
contains two capacitors and two adjustable potentiometers RA and
RB. Block 4 is the helium gas supply. The helium flow rate was set
to approximately 4.6 L/min. Electrical measurements were
conducted with a Tektronix TDS3014C Digital Phosphor
Figure 1. CAP set-up: (a) Configuration of CAP generation device. (b) electrical circuit diagram.
doi:10.1371/journal.pone.0073741.g001
Table 1. Different CAP parameter (output voltage and
resistance value) effects for MSC growth in vitro.
Condition
Resistance
A (V)
Resistance
B (V)
Output
Voltage (KV) Effects
1 3000 3000 3.28
2 3000 3700 3.28 2
3 3700 3000 3.28 2
4 3700 3700 3.28 +
5 3000 3000 3.68 +
6 3000 3700 3.68 2
7 3700 3000 3.68 2
8 3700 3700 3.68 2
Note: ‘‘+’’ means positive effects (i.e., non-inhibited or increased cell
proliferation when compared to untreated group) for MSCs; ‘‘2’’ means
negative inhibited effects (i.e., decreased cell proliferation when compared to
untreated group) for MSC growth.
doi:10.1371/journal.pone.0073741.t001
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Oscilloscope. Optical measurements were made with a 100 mm
probe 3 cm away from the front of the nozzle (Figure 2a). In order
to measure the radius of the plasma jet, a holder with a horizontal
trench (Figures 2a and 2b) was used to move the probe
horizontally. Spectra of the jet were recorded at 0, 1, and 2 mm
from the jet center. In addition, a radical experiment was
conducted to measure the radius of the plasma jet.
Figure 2. Radial measurement of helium plasma jet: (a) plasma tube aligned with optical probe (b) schematic diagram of holder and
probe; (c) intensity of major species drop along radius.
doi:10.1371/journal.pone.0073741.g002
Figure 3. Emission spectrum of helium cold plasma at an output voltage of 3.68 kV.
doi:10.1371/journal.pone.0073741.g003
Cold Plasma for Breast Cancer
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e73741
MSC and BrCa responses under different CAP treatment
conditions and exposure time
MSC and BrCa cells were seeded at a density of 50,000 cells/
well on two 48 well-plates, respectively. 300 ml of media was added
into each well and all of the cells were cultured for 24 hours before
CAP treatment. The distance between the CAP nozzle and plate
bottom was 3 cm during all treatment conditions. All treatments
were conducted at about 25uC (room temperature). After 30 s
CAP treatment, media were replaced and cells were cultured for
additional 24 hours. Firstly, MSCs were treated with different
CAP conditions, including output voltage and resistance value as
listed in Table 1. These parameters can alter the CAP discharge
power and affect cell behaviors. The attached cell numbers after
24 hours of culture were compared to untreated controls.
Two conditions (4 and 5 in Table 1) without negative inhibited
influence to MSCs were prescreened, selected and applied to BrCa
cells for 0, 30, 60, and 90 s. After the CAP treatments under the
selected conditions, separately treated MSCs and BrCa cells were
cultured for an additional 24 hours under standard cell culture
conditions. After required culture time, the MTS assay reagent
CellTiter96VR Aqueous One solution (Promega) was used to
quantify attached cell number. In addition, a live/dead viability/
cytotoxicity kit for mammalian cells (Molecular Probes) was used
to evaluate cell viability after CAP treatment (condition 5 for 0, 30,
60, 90 and 120 s). Briefly, after 24 hours, each well was rinsed
twice with phosphate buffer saline (PBS). A working solution of
4 mM ethidium homodimer (EthD-1) and 2 mM calcein AM was
prepared as described previously [20]. After rinsing, 80 mL of
working dye solution was added to each well and incubated at
37uC 30 min before imaging each well with a fluorescent
microscope (Olympus BX 60). A mosaic image was collected in
Image ProH to show and compare the distribution of live and dead
BrCa cells and MSCs under 0, 30, 60, 90 and 120 s CAP
treatments.
BrCa and MSC proliferation under CAP treatments
BrCa and MSC were pre-seeded at 50,000 cells/well with
300 mL of media per well in a 48 well-plate and cultured for
24 hours. Similar to the previous CAP treatment section, CAP was
used to treat both of the BrCa cells and MSCs. The optimal
conditions for selectively ablating BrCa cells with minimally
influence of MSCs were applied daily for 0, 30, 60 and 90 s. The
cells were cultured in respective media for 1, 3, and 5 days.
At predetermined time points, MTS assay was used to quantify
cell number. Briefly, cells were lift with Typsin EDTA, and added
to a new 96 well plate with 100 mL of suspension per well. 20 mL
of the MTS reagent was added to each well and incubated for
1 hour. Absorbance was measured at 490 nm using a UV-vis
spectrophotometer.
BrCa cell migration study after CAP treatment
In order to evaluate metastatic BrCa cell migration behavior
after CAP treatment, the Matrigel Transwell Migration assay
using a transwell chamber in conjunction with 8 mm membrane
filter inserts was chosen. The pre-seeded BrCa cells were treated
by CAP daily with different predetermined treatment times (0, 30,
60 and 90 s, condition 5). Then CAP treated cell were lifted and
concentrated via centrifugation and further suspended in serum-
free DMEM medium. 50,000 cells were added to the upper
transwell chamber, whereas the lower chamber was filled with
complete medium. After 24 hours of incubation in 5% CO2 at
37uC, BrCa cells which had migrated through the membrane to
the lower surface were fixed and stained with a Differential Quik
Stain Kit. The numbers of cells on the lower surface of the
membrane were counted by a light microscope (10x).
2D wound healing assay of BrCa cells after CAP
treatment
The wound healing assay was used to study BrCa cell migration
velocity and cell interactions after 0, 30, 60 and 90 s CAP
treatment. Treated BrCa cells (500,000 per dish) were seeded in a
petri dish and allowed to adhere for 24 hours. Confluent
monolayer cells were straightly scratched by a pipette tip, to
simulate a wound environment, and then washed three times with
PBS to remove cell debris and suspended cell. Fresh medium was
added, and the cells were allowed to close the ‘‘wound’’ for
24 hours. Images of cells migrating into the wound space were
captured at 0 to 24 hours via a confocal microscope. The rate of
wound closure, BrCa cell migration velocity and migration
distance of the first line of bottom of scratch in first 9 hours were
calculated.
Statistics
The cellular experiments were run in triplicate and repeated
three times for each group. Data are presented as the mean value
6 standard error mean (SEM) and were analyzed with student’s t-
Figure 4. CAP effects on cell growth: MSC and BrCa cell growth
under condition 5 (RA=3000 V, RB=3000 V, output voltage is
3.68 KV) in 0s, 30 s, 60 s, 90 s of CAP treatment. Data are mean
6 SEM, n = 9; *p,0.05 when compared to BrCa cells under 30 and 60 s
CAP treatments.
doi:10.1371/journal.pone.0073741.g004
Figure 5. CAP effects on cell growth: MSC and BrCa cell growth
under condition 4 (RA=3700 V, RB=3700 V, output voltage is
3.28 KV) in 0 s, 30 s, 60 s, 90 s of CAP treatment. Data are mean
6 SEM, n = 9; *p,0.05 when compared to BrCa cells under 30 and 90 s
CAP treatments.
doi:10.1371/journal.pone.0073741.g005
Cold Plasma for Breast Cancer
PLOS ONE | www.plosone.org 4 September 2013 | Volume 8 | Issue 9 | e73741
test for pair-wise comparison. Statistical significance was consid-
ered at p,0.05.
Results
CAP characterization
Figure 3 shows a typical spectrum of helium CAP jet interacting
with the ambient air. The identification of emission lines and
bands were mainly according to Volotskova et al [21] and
Georgescu et al [22]. In the significant range of 250–300 nm
there are very weak emission lines, which are interpreted as NO
[23]. In addition, the inactivation effect on bacteria by ultraviolet
radiation is mostly related to biological damage caused by UV
wavelengths of 200–280 nm. Thus it can be concluded that UV
photons are not a major CAP species with our setup. In the
wavelength range of 300–550 nm, their magnitudes are at most a
few thousandths of the highest peak, N2
+ (391 nm). The species
lines between 300–500 nm are still undetermined [2,4]. Other
apparent CAP species were interpreted as He lines between 550–
750 nm. Atomic oxygen (O) (emission lines at 777 nm) is believed
to have significant biological effects, and was present in our
generated CAP. The CAP jet is a highly complex environment
which combines the comprehensive effects of different ions and
neutrals. From the emission spectra data shown here, O (777 nm),
OH/O3 (309 nm), N2
+ (391 nm), N2 or NO lines (316, 337, 358,
427.5 nm) are the domain species of the spectra. Repeated
measurements (not shown) were performed to confirm the initial
results.
Figure 6. Fluorescence microscopy images. Live (green) and dead (red) BrCa cells (A–E) and MSCs (F–J) under 0, 30, 60, 90 and 120 s
of CAP treatment.
doi:10.1371/journal.pone.0073741.g006
Cold Plasma for Breast Cancer
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Radical measurement of the CAP jet was conducted with the
holder shown in Figure 2. Helium flow rate was kept at 4.6 L/min.
Input and output voltage was maintained at 11.8 V, and 3.76 kV,
respectively. With a spectra of different positions recorded, the
emission drops of major CAP species were plotted in Figure 2 (c).
We can see that the radius of the jet is roughly 2 mm (i.e., ,4 mm
diameter).
In addition, it was observed that the plasma between the two
electrodes formed by optical emission is much stronger than the
plasma plume. Therefore, the spectra measured in our experiment
may not be the entirely emission of the plasma jet. Furthermore, it
should be pointed out that the probe placed in front of the jet may
cause the perturbation of the helium plasma jet.
Different BrCa cell and MSC responses under varied CAP
conditions
Given its potential to interact with tissue or cells without a
significant temperature increase, CAP holds great potential for
minimally invasive cancer treatment. As mentioned previously,
possible underlying mechanisms with regards to CAP’s high
selectivity towards cancer cells may be attributed to complex CAP
compositions. In this study, we varied two CAP jet parameters
(i.e., voltage and resistance) in order to achieve a desirable CAP
composition and cellular responses.
Table 1 shows that different CAP voltage and resistance
conditions lead to either a positive or negative effect on healthy
MSCs. The ’positive effect’ means non-inhibited or increased cell
growth after CAP treatment. In other words, MSC can keep and
improve their proliferation after the treatment. ‘Negative’ means a
decreased cell growth number and changed morphology after
CAP treatment. Among all conditions, conditions 4 and 5 reveal
desirable positive effects on MSCs. Moreover, Figure 4 shows the
selective effect of CAP treatment on MSC and BrCa cells under
the condition 5 (RA=3000 V, RB= 3000 V, and 3.68 KV output
voltage). Within 30 s treating time, the MSC growth was greatly
improved while BrCa cell growth was inhibited. In contrast,
Figure 5 showed the effects of condition 4 on both MSCs and
BrCa cells. Although MSC growth was greatly enhanced initially,
there is not significant selectivity shown here. After 60 s treatment,
both MSC and BrCa cell densities were decreased. Thus, the
condition of RA=3000 V, RB=3000 V and 3.68 KV output
voltage is the selected optimal treatment condition for the later
experiments.
Figure 6 illustrates the viability of metastatic BrCa and MSCs
under 0, 30, 60, 90 and 120 s of selected CAP treatment condition
5. The images show typical and representative areas of the treated
cells. Our results show that at short durations of CAP treatment
(30 s), MSCs grew well when compared to both controls and the
same treated BrCa cells. After 60 s of CAP treatment, significant
differences between BrCa and MSC responses were observed.
Greater amounts of metastatic BrCa cells were detached and lysed
by CAP while MSCs kept growing normally with fewer dead cells
(Figures 6C–E and 6H–J). Moreover, our results demonstrated
that, for the first time, CAP treatment may selectively kill BrCa
cells while leaving MSC growth unaffected. Although the
underlying mechanism is not completely clear, we believe that a
unique ROS (plasma killing species) and reactive nitrogen species
(RNS, plasma healing species, such as NO, N2, N2
+) environment
Figure 7. CAP treated MSC proliferation. MSC 1, 3 and 5 day
proliferation under different daily CAP treatments. Data are mean 6
SEM, n= 9; *p,0.05 and #p,0.01 when compared to 60 and 90 s daily
treatment after day 1 and day 3; **p,0.05 and ##p,0.01 when
compared to 90s treatment after day 1 and day 3; &p,0.01 when
compared to 90 s daily treatment after day 5 and &&p,0.05 when
compared to 60s daily treatment after day 5.
doi:10.1371/journal.pone.0073741.g007
Figure 8. CAP treated BrCa cell proliferation. Significantly
inhibited BrCa cell 1, 3 and 5 day proliferation under different daily
CAP treatments. Data are mean 6 SEM, n= 9; *p,0.01 when compared
to 0 s and 30 s daily treatment after day 1; **p,0.01 when compared to
all other samples after day 3 and day 5. #p,0.01 when compared to
0 s and 30 s daily treatment after day 3 and day 5; and &p,0.01 when
compared to untreated samples (0 s) after day 3 and day 5.
doi:10.1371/journal.pone.0073741.g008
Figure 9. BrCa cell migration via Transwell Migration assay.
CAP treatment decreased invasion of BrCa in matrigel transwell. Cells
were treated with CAP in 0 s, 30 s, 60 s and 90 s. CAP treatment
influenced invasion of BrCa cell in matrigel transwell.
doi:10.1371/journal.pone.0073741.g009
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created by CAP may contribute to the adverse and beneficial cell
responses as shown in our study.
Cell adhesion and viability data after different CAP treatments
showed that the CAP device’s voltage, resistance, and treatment
duration played a significant role in modulating different cellular
responses. Furthermore, in addition to single CAP treatments,
MSCs and BrCa cells were periodically exposed to daily CAP
treatment for up to 5 days. Both MSC and BrCa cell proliferation
during the daily CAP treatments were evaluated and compared.
The results of 1, 3, and 5 day MSC proliferation studies are shown
in Figure 7. Under short (30 s and 60 s) daily CAP treatments,
MSCs remained intact and proliferated well when compared to
untreated controls (0s treatment). Under 90 s daily treatment,
MSC cell density was lessened when compared to short term CAP
treatment. In contrast, Figure 8 reveals a significantly different
BrCa proliferation profile under the same daily CAP treatment
regimen. Cancer cells were more sensitive to CAP when compared
to untreated BrCa cells (0 s), all CAP-treated BrCa cells showed a
significant inhibited proliferation rate after 3 and 5 days.
Especially after 60 s and 90 s daily CAP treatment, cancer cells
virtually stopped expanding. According to the results, selective
ablation time for significantly lysing BrCa with the smallest
possible effect on MSC is between 30–60 s.
Inhibited BrCa cell migration after CAP treatment
In addition, we investigated the CAP effects on the metastatic
BrCa cell migration behavior via a transwell migration assay. Cell
migration and invasion were significantly decreased in all three
CAP treated BrCa cell groups (Figures 9 and 10). The number of
migrated 90 s CAP treated cells decreased by nearly 3.5 folds
when compared with control. The number of migrated 60 s CAP
treated cells was reduced by 2 folds when compared to control.
Figure 10. Quantified BrCa cell invasion in matrigel transwell.
Data are mean 6 SEM, n = 9; *p,0.001 when compared to all other
treatments. **p,0.01 when compared to 0 s, and 30 s daily treatment.
***p,0.001 when compared to 0 s controls.
doi:10.1371/journal.pone.0073741.g010
Figure 11. Wound healing assay: BrCa cells treated with different CAP time were captured every 5 hours.
doi:10.1371/journal.pone.0073741.g011
Cold Plasma for Breast Cancer
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These results exhibited that CAP play an important role in
mediating migration of metastatic BrCa cells.
To further analyze cell migration and velocity after CAP
treatment, a wound healing assay was performed to confirm the
CAP inhibitory effects in BrCa cell migration. When started, the
mean wound length was about 400 mm. After 20 hours incuba-
tion, the distance of untreated control was reduced to 0 (Figure 11).
Consistent with the transwell migration results, CAP treated BrCa
cells for 30, 60 and 90 s showed a significantly slow closure rate
when compare to the control group. For 60s and 90s CAP treated
BrCa cells, there was little to no wound closure after 20 h. 60 s
CAP treated BrCa closed by 90.7%, whereas 90 s CAP treated
BrCa only achieved 63.7% closure (Figure 12). Consistent with cell
closure percentage data, Figure 13 shows the single cell migration
tracks of the first line of the scratch showed the greatly slow
migration of 30 s, 60 s and 90 s CAP treated BrCa cells after
9 hours migration. In addition, CAP treated cells presented a
decrease in the number of high-velocity movements (Figure 14A),
and exhibited a significant decrease in total migration distance
(Figure 14B).
Discussion
Tumor metastasis is the movement of tumor cells from a
primary site to a secondary site (such as bone), which occurs in a
series of steps including cancer cell migration, adhesion, prolifer-
ation, invasion and vessel formation, etc. All of those steps are
regulated by complex mechanism including microenvironment
interaction, gene expression and enzymes regulation. Our
experiments demonstrated that through adjustment of resistance
and output voltage of CAP jet, with the change of plasma emission
intensity and power, a mild dose with suitable discharge power can
be acquired to efficiently kill metastatic BrCa cells while keeping
healthy MSC alive. Due to the observed significantly inhibited
migration of BrCa cells under CAP treatment, one of the possible
effects of moderate intensity and power plasma treatment may
contribute to alter BrCa cell surface receptor functions [24] (such
as integrin mediating cell adhesion and migration) [25]. Further-
more, the present research demonstrated that CAP treatment
plays an important role in tumor therapy via immediate cell lyses
[26]. Cell death in response to CAP treatment can be correlated to
all aspects of the treatment condition, especially in the dose range.
This is primarily a result of many likely factors including the
presence of charged electrons, ROS, and RNS [27]. Furthermore,
Figure 12. Representation of the rate of closure for each condition: untreated BrCa, CAP treated 30 s, 60 s, 90 s. Data are mean 6
SEM, n = 9; *p,0.01 when comparing the untreated group with CAP treatment of 30 s, 60 s and 90 s.
doi:10.1371/journal.pone.0073741.g012
Figure 13. Representative microscopy images of BrCa migra-
tion pathway. Cell tracks of the first line of bottom of scratch for each
condition in first 9 hours: untreated BrCa cells, CAP treated 30 s, 60 s,
and 90 s.
doi:10.1371/journal.pone.0073741.g013
Cold Plasma for Breast Cancer
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plasma-induced DNA damage may likely initiate cellular change.
Although the possible underlying mechanisms of cell death
induced by CAP remain unclear, previous research has elucidated
several potential mechanisms for diverse cell responses under CAP
[20,28,29]. For example, ROS in CAP is reported to play a large
role in cancer cell and bacterial ablation [30–32]. CAP induced
DNA-damage is purported to be attributed to ROS-induced DNA
lesions caused by point mutations [33]. Recent reports also
indicated that lipid peroxidation and oxidative DNA damage in E.
coli was caused by intracellular ROS formation of CAP [34]. In
our study, we observed that high doses of CAP treatment can
significantly decrease cancer cell viability, which are believed to be
mainly caused by ROS. In addition to DNA lesions caused by
ROS, DNA precursor oxidation also has the potential to influence
cell apoptosis [35,36]. Also, it has been reported that CAP induced
pH change of cell culture media may lead to cell apoptosis.
However, our study showed that our medium pH change under
the current CAP set-up was considered to be negligible.
Furthermore, thermal effect on cells is virtually negligible in our
study, which corresponds with our previous research [15].
Physically, CAP exposure can create temporal openings of the
cell membrane, usually over a microsecond timescale, allowing for
CAP specie transportation. This results in different cell responses
[37]. In addition, low energetic UV photos may indirectly affect
genes and cause cell death [37]. Moreover, since cancer cells
proliferate much faster than normal cells, it has been reported that
CAP can selectively target cancer cells by interfering with the
mitotic cell cycle [18]. Thus, the observed selective effects of CAP
in our study may be attributed to the significant difference in the
distribution of BrCa cells and MSCs within the cell cycle, thus
rendering cancer cells more sensitive to CAP treatment. Under
fluorescence microscopy, specifically within the context of a live
dead assay, we can clearly see that treated BrCa cells exhibited a
significantly decreased viability with CAP treating.
Current results show that in vitro wound closure assay results
were in line with the transmigration assay results. CAP treated
BrCa cell wound areas close more slowly than untreated ones
during a 20 h culture period. Interestingly, after 60 s and 90 s
CAP treatment, when wounds reached close to full closure, BrCa
cells in the first line of the bottom of the wound migrated in a
horizontal direction instead of a vertical one. Consistent with the
cell adhesion and proliferation studies, it is postulated that CAP
exposure may also affect genes related to cell migration and
metastasis, which play an important role in either horizontal
(wound healing assay) or vertical (transmigration assay) directional
migration.
Our current study focused on the initial interactions between
CAP, MSCs and BrCa cells in order to optimize the parameters.
The next step will be focused on devising an in vitro co-cultured
model with a bone-tumor microenvironment and utilizing an in
vivo model to further study CAP’s effects. For future clinical
applications, the CAP can be administered to any tumor locations
in breast cancer patients via an endoscopic tube for endoscopic
treatment. If the size of the solid tumor is large as is common in
middle/late stage breast cancer patients, before conventional
surgery, we expect that direct endoscopic exposure of CAP to the
tumor can highly efficiently shrink the size of tumor; after surgery
removal procedure, CAP can be further employed to kill existing/
remaining cancer cells and prevent further metastases.
Conclusions
In summary, this study investigated CAP generation conditions
(voltage, resistances, treatment duration and frequency) for
selectively killing BrCa cells. BrCa cells were found to be more
sensitive to these CAP treatments than MSCs under plasma dose
conditions tested. It has been demonstrated for the first time that
CAP can selectively ablate metastatic BrCa cells in vitro without
damaging healthy MSCs. The results suggest the great potential of
CAP to be highly selective towards breast cancerous cells, resulting
in tumor remediation with near complete ablation while main-
taining healthy cells and tissue intact.
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